Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma.

Blackstone Life Sciences V fund closed at its hard cap of $4.6 billion of total capital commitments, marking the largest life sciences private fund that raised to date.

Early data from Moderna Inc.’s COVID-19 vaccine – the first to be tested in the United States – showed that it produced protective antibodies in a small group of healthy volunteers, the company said.

BioSpace provided an update on recent personnel movement within the healthcare industry, including Cheryl R. Blanchard being named president and chief executive officer of Anika Therapeutics.

Bolt Biotherapeutics Inc., a private clinical-stage biotechnology company, tapped Edith Perez, M.D., as chief medical officer.

Recent personnel updates within the healthcare industry include Foundation Medicine veteran Thomas Civik being named president and chief executive officer of Five Prime Therapeutics.

Mirati Therapeutics made several changes to the executive management team as the company continues to accelerate the development of its KRAS and sitravatinib programs through registrational trials and prepares for commercialization.

Copenhagen-based Zealand Pharma announced a bid to buy substantially all the assets from New Jersey-based Valeritas in $23 million in cash and taking on certain liabilities.

BioNTech will acquire Neon Therapeutics Inc. in an all-stock transaction valued at approximately $67 million.

Sanofi is ending diabetes and cardiovascular (DCV) research efforts as part of a revamp to narrow the number of the company’s business units in the hope of bolstering growth and profit.